Wednesday, January 31, 2018

8:30 a.m. | Registration Opens

10:00 a.m. | Plenary Lecture

  • Role of very low carb diets in T1D management (Belinda Lennerz, M.D., Ph.D., Harvard Medical School)

10:45 a.m. | Session 1: Advances in Beta Cell Regeneration

  • Residual beta cell mass in T1D (Martha Campbell-Thompson, DVM, Ph.D., University of Florida College of Medicine)
  • Interplay of islet cell types during fetal development (Hung-Ping Shih, Ph.D., City of Hope)
  • Alpha to beta cell transdifferentiation (Fabrizio Thorel, Ph.D., Universite de Geneve)
  • Metabolic stress and beta cell regeneration (Yuval Dor, Ph.D., The Hebrew University-Hadassah Medical School)
  • Do human islets respond to gastrin? (Young Investigator Talk) (Ayelet Lenz, Ph.D., City of Hope)

1:20 p.m. | Session 2: nPOD and HiRN Updates

  •  nPOD updates (Mark Atkinson, Ph.D., University of Florida College of Medicine)
  • HiRN updates (Maike Sander, M.D., University of California, San Diego)

2:50 p.m. | Plenary Lecture

  • Clinical trials: TrialNet ATG/CGSF new onset study (Michael Haller, M.D., University of Florida College of Medicine)

4:30 p.m. | Keynote Dinner Lecture

  • Omics of diabetes – Personalized diagnosis and treatments (Michael Snyder, Ph.D., Stanford University)

Thursday, February 1, 2018

8 a.m. | Rachmiel Levine Award Lecture

8:45 a.m. | Session 1: Encapsulation and Mechanical Immunoprotective Approaches in Beta Cell Replacement

  • Macroencapsulation approaches (Evert Kroon, Ph.D., ViaCyte, Inc.)
  • Biosynthetic materials for islet encapsulation and transplantation (Andres Garcia, Ph.D., Georgia Institute of Technology)
  • Biological scaffolds: Miami Omental islet transplant (Rodolfo Alejandro, M.D., University of Miami)
  • Mechanical immune protection of transplant islets: Clinical perspective (Olle Korsgren, M.D., Ph.D., University of Uppsala)

11:05 a.m. | Session 2: Control of Beta Cell Function

  • Control of insulin secretion by cytochrome C and signaling in impaired islets (Ian Sweet, Ph.D., University of Washington School of Medicine)
  • Neural control of beta cell function (Sarah Stanley, MBBCh, Ph.D., Mount Sinai School of Medicine)
  • Islet cell heterogeneity: Hubs and spokes (Guy Rutter, Ph.D., Imperial College London)
  • Pumping up beta cell function and durability (Debbie Thurmond, Ph.D., City of Hope)

2:30 p.m. | Round Table Discussion

  • Virus, B-cells, beta-cell function as endpoint in immunotherapy, autoimmunity vs. innate immunity (Panel Discussion to include: Carla Greenbaum, M.D.; David Harlan, M.D.; Olle Korsgren, M.D., Ph.D.; Bart Roep, Ph.D.; and Matthias von Herrath, M.D.)

4 p.m. | Session 3: Epigenetics of Diabetes

  • Epigenetics and pancreatic beta cell maturation (Sangeeta Dhawan, Ph.D., City of Hope)
  • Association of epigenomic DNA methylation variations with glycemic control and metabolic memory of diabetes complications (Rama Natarajan, Ph.D., City of Hope)
  • Epigenome-wide association of liver methylation patterns and complex metabolic traits (Matteo Pellegrini, Ph.D., University of California, Los Angeles)
  • The role of diet and exercise in modifying the epigenetic landscape in type 2 diabetes (Romain Barrès, Ph.D., University of Copenhagen)

6 p.m. | Poster Session

Friday, February 2, 2018

8 a.m. | Arthur Riggs Award Lecture

8:45 a.m. | Session 1: Metabolism in Obesity and Diabetes

  • FGF21 regulates metabolism through adipose dependent and independent mechanisms (Matthew Potthoff, Ph.D., University of Iowa)
  • RAGE, lipolysis and the immunometabolic sphere in the regulation of energy expenditure (Ann Marie Schmidt, M.D., NYU Langone Medical Center)
  • Macrophages, thermogenesis and adipose metabolism (Christoph Buettner, M.D., Ph.D., Mount Sinai School of Medicine)
  • Immunometabolism (Michael Czech, Ph.D., University of Massachusetts School of Medicine)

11:05 a.m. | Session 2: Molecular and Cellular Immunology of Diabetes

  • Insights from the type 1 diabetes pancreas (Sarah Richardson, Ph.D., University of Exeter Medical School)
  • Cellular therapy (Jaap-Jan Zwaginga, M.D., Ph.D., Leiden University Medical Center)
  • Loss of IDO in human pre-diabetes (Florence Anquetil-Besnard, Ph.D., La Jolla Institute for Allergy and Immunology)
  • Association of serum micro RNAs with islet autoimmunity, disease progression and metabolic impairment in relatives of T1D (Alberto Pugliese, M.D., University of Miami)
  • Anti CD6 to circumvent autoimmunity in T1D (Young Investigator Talk) (Jose Enrique Montero Casimiro, M.D., Ph.D., City of Hope)

3 p.m. | Session 3: TrialNet and ITN Updates

  • TrialNet updates (Carla Greenbaum, M.D., Benaroya Research Institute)
  • ITN updates (TBD)

4:30 p.m. | Session 4: Tregs and Diabetes

  • Tregs in human pediatric T1D (Carolin Daniel, Ph.D., Helmholtz Zentrum Munich)
  • CAR Tregs in allo transplantation (Timothy Tree, Ph.D., King’s College London)
  • Haploidentical mixed chimerism for cure of new onset T1D in preclinical models (Defu Zeng, M.D., City of Hope)
  • Treg clinical trial for autoimmune diseases (Qizhi Tang, Ph.D., University of California, San Francisco)


Saturday, February 3, 2018

8 a.m. | Plenary Lecture

  • Energy sensing and metabolism-Implications for treating diabetes (Gregory Steinberg, Ph.D., McMaster University)

8:45 a.m. | Session 1: Personalized Medicine

  • Precision diabetes: Learning from monogenic diabetes (Kashyap Patel, Ph.D., University of Exeter Medical School)
  • Identification of RUNX1 as a mediator of aberrant angiogenesis in proliferative diabetic retinopathy (Leo Kim, M.D., Ph.D., Harvard Medical School)
  • Genome wide physical activity interactions in adiposity (Mariaelisa Graff, Ph.D., University of North Carolina at Chapel Hill)
  • Vetting and advancing individualized medicine: Issues and strategies (Nicholas Schork, Ph.D., The Scripps Research Institute)

11:05 a.m. | Session 2: Extracellular Vesicles and Diabetes (1)

  • The exosome paradigm of intracellular communication (Philip Stahl, Ph.D., Washington University School of Medicine)
  • Extracellular RNA and diabetes (Kendall Van Keuren-Jensen, Ph.D., The Translational Genomics Research Institute)
  • MSC-derived EV attenuate immune responses in two autoimmune murine models: T1D and Uveoretinitis (Ryang Lee, Ph.D., Texas A&M University)

1 p.m. | Session 3: Extracellular Vesicles and Diabetes (2)

  • Primary human and rat beta cells release the intracellular autoantigens GAD65, and proinsulin in exosomes together with cytokine-induced enhancers of autoimmunity (Edward Phelps, Ph.D., University of Florida)
  • Tissue specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue (Prashanth Vallabhajosyula, M.D., Hospital of the University of Pennsylvania)